Index

Abortion Act 1967, 9, 13 fetal anomaly, 153 abortion counselling, see support and counselling abortion incidence complications method (AICM), 25 Abortion Law Reform Act (2008) (Vic), 240 abortion methods, 89 grief resolution and, 89 historical approaches, see historical perspectives medical abortion, see medical abortion mortality and, 123-4 surgical abortion, see surgical abortion acceptability TOPFA (termination of pregnancy for fetal anomaly), 157-8 vacuum aspiration abortion (VA), 72 access to abortion, see human rights acute intermittent porphyria, 137 Advancing New Standards in Reproductive Health (ANSIRH), 251 Africa, Protocol to the African Charter on Human and Peoples' Rights on the Rights of Women in Africa, 247 age profiles, 29-30 second trimester abortions, 204-7 allergic reactions, local anaesthesia, 99 American Congress of Obstetricians and Gynecologists (ACOG), 251 professional responsibilities, 188-9 anaemia, 136 post medical abortion, 128-9 anaesthesia complications related to, 126

general, see general anaesthesia international approaches, 102 local, see local anaesthesia for medical abortion (TOPFA), 156 medical co-morbidity and, 134 indications, 134 obesity and, 135 pre-operation, 134 types of anaesthesia, 134 analgesia dilatation and evacuation (D&E), 90, 91 early medical abortion (EMA), 67,103 medical abortion (higher gestation), 85 non-steroidal anti-inflammatory drugs (NSAIDs), 85 vacuum aspiration abortion (VA), 73 see also pain management antibiotics complications and, 123 dilatation and evacuation (D&E), 95 prophylactic, 127 early medical abortion (EMA), 66 vacuum aspiration abortion, 73 World Health Organization (WHO) guidance, 129 sexually transmitted infections (STIs), 66 anxiety, pain and, 102-3 association and causality, 163 - 5analogous associations, 165 biological mechanism, 164 consistency, 164 definition, 163 dose-response effect, 164 epidemiology and, 164 research evidence, 164 specificity, 164 strong association, 164 temporal factors, 164

Association of Reproductive Health Professionals (ARHP), 251 asthma, 136 attitudes to abortion, 10-14 Catholic, 11 feticide, 146-8 health professionals, 12-14, 212 judgementalism in abortion care, see health professionals legal, 12 philosophical, 10-11 public, 12 repeat abortions, 193, 216-17 stigma, see stigma Australia, 236-43 Australian Capital Territory (ACT), 240 historical approaches, 237-9 legal context, 236-7 mifepristone, 63 Offences Against the Person Act (OAP) (1861), 237 Tasmania, 241-2 conscientious objection, 242 Reproductive Health (Access to Terminations) Act 2013 (Tas), 241 Victoria, 240-1 Abortion Law Reform Act (2008) (Vic), 240 conscientious objection, 241 termination of pregnancy for fetal anomaly (TOPFA), 240 Western Australia, 239 autonomy (of woman), 16 biparietal diameter, 56 bleeding anaemia, 128-9 dilatation and evacuation (D&E), 95 disseminated intravascular coagulopathy (DIC), 125

haemorrhage, *see* haemorrhage breast cancer, 168, 169, 177–8

255

256

Index

caesarean section, uterine scars, 139 Canada, telemedicine (Women on Web), 228-9, 231-2 cancer, breast, 168, 169, 177-8 cardiovascular disease, 138 Catholicism, 11 Center for Reproductive Rights, 251 cervical laceration, surgical abortion, 124 dilatation and evacuation (D&E), 94 cervical preparation dilatation and evacuation, see dilatation and evacuation (D&E) medical co-morbidity, 134 obesity, 135 surgical problems and, 139 vacuum aspiration abortion, see vacuum aspiration abortion (VA) Chiba needle, 148, 149, 150 Chlamydia trachomatis, 66, 127 'choice' argument autonomy (of woman), 16 women's rights and, 16 coercion, 44, 48 Committee on the Elimination of Discrimination against Women (CEDAW), 189 complete abortion, rates and complications, 65 compliance, 107 follow-up clinic visit, 107 complications of abortion continuing pregnancy, see follow-up of dilatation and evacuation, see dilatation and evacuation (D&E) factors associated, 31 abortion method, 123-4 abortion provider's skill, 123 antibiotics and cervical priming, 123 gestational age, 123 in safe abortions, 123-4 future pregnancy complications, 95 incomplete abortion, see retained products of conception (RPOC) medical abortion, 128-30 continuing pregnancy, 130 early, 128

heavy or prolonged bleeding, 128-9 higher gestation, 84-5, 130 incomplete abortion, 129-30 infection, see infection postabortion (endometritis) uterine rupture, see uterus second trimester abortion, 157, 202 surgical abortion, 124-8 anaesthesia-related complications, 126 cervical laceration, 124 continuing pregnancy, 127-8 dilatation and evacuation (D&E), see dilatation and evacuation (D&E) disseminated intravascular coagulopathy (DIC), 125 haematometra, 126 haemorrhage, 125 incomplete abortion, 126 infection, see infection postabortion (endometritis) mid-level provision, 221-2 uterine perforation, see uterus vacuum aspiration abortion (VA), see vacuum aspiration abortion (VA) vasovagal reaction, 124 see also morbidity (abortionrelated) Concept Foundation, 251 conscience/conscientious acts, 187 - 90conscientious commitment, 187-8 conscientious objection, 187, 204, 212-14 Australia (Victoria), 241 General Medical Council (GMC) (UK), 213 Nursing and Midwifery Council (NMC) (UK), 213 Royal College of Obstetricians and Gynaecologists (RCOG), 213 Tasmania, 242 USA, 213-14 definition, 188 guidelines, American Congress of Obstetricians and Gynecologists (ACOG), 188-9

refusal of care, 188-90 Committee on the Elimination of Discrimination against Women (CEDAW), 189 health system obligations, 189-90 professional responsibilities, 188-9 right of, 188 right to, 187 stigma and, 187 consensual issues principle of retraction, 21 telemedicine, 233 see also consent consent 66, 72, 90, 227, 232, 233 dilatation and evacuation (D&E), 90 vacuum aspiration abortion (VA), 72 see also consensual issues continuing pregnancy medical abortion, 130 surgical abortion, 127-8 see also follow-up contraception advice at time of abortion, 181-2 anti-progesterone drugs as, 62 efficacy, 179-80 emergency contraception, 179 medical co-morbidity, 140 partner violence and, 199 postabortion, 66, 68, 72, 110-11, 114-21 after medical abortion, 111, 118 after surgical abortion, 96, 111, 117-18 commencement, 110-11, 117 - 19cost-effectiveness, 119 current research, 119-120 hormonal methods, 117 intrauterine device (IUS/ IUD), 111, 116-7, 118 long-acting reversible contraceptive (LARC), 115, 119 mid-level providers, 223 ovulation, return of, 115 repeat abortions and, 198-9 risk of subsequent abortion and, 115-7 repeat abortions and, 193, 198, 199 unsafe abortions and, 114

Index

counselling, see support and counselling cremation and burial fetal remains, 216 Institute of Cemetery and Crematorium Management (ICCM), 216 TOPFA (termination of pregnancy for fetal anomaly), 159 criminal abortion (historical context), 8 culture, sex-selective abortion and, 20 Czech Republic, 171 decision-making process coercion, 44, 48 contradictory feelings and complexity, 37-8 informed decision, 43 in legally restricted jurisdictions, 50 male progenitors and, 35-6 method of abortion, 84 grief resolution, 89 vacuum aspiration abortion (VA), 72 planning and pregnancy, 34 setting for EMA, 65 support and counselling, 43-4, 178, 179 additional support requirements, 45-6 case example, 47-8 duration, 46 function of, 46-7 key aspects, 44 with significant others, 48 timing, 37 TOPFA, see TOPFA (termination of pregnancy for fetal anomaly) deep sedation, 101, 102 demographics (abortion), see epidemiology denied abortion, 170-1, 248 effects on the child born, 171 effects on the woman, 170-1 outcomes and, 42-3 second trimester, 202 diabetes mellitus, 135-6 digoxin, feticide, 94, 145 administration procedure, 94, 150, 150-1 failed feticide, 151

Dilapan-S®, 91 dilatation and evacuation (D&E), 88-97 background, 88-9 cervical preparation, 90-2 Dilapan-S[®], 91 laminaria, 91 mifepristone, 92 misoprostol, 92 osmotic dilators' placement, 91-2 pain management, 91 complications, 81, 94, 157 bleeding, 95 cervical laceration, 94 incomplete abortion, 95 infection, 95 long-term sequelae, 95 maternal mortality, 94 uterine perforation, 94 uterine scar rupture and, 86 dilatation and extraction (D&X), 88,93 feticide, 94 indications, 88 operative procedure, 92-3 forceps, 93 instruments, 92 vacuum aspiration, 93 placenta accreta, 90 postabortion care, 95-6 pre-procedure assessment, 90 consent, 90 pain management, 90 ultrasound scanning in, 90 prevalence, 88, 89-90 safety and effectiveness, 89 maternal mortality, 89 setting, 88 dilatation and extraction (D&X), 88,93 disseminated intravascular coagulopathy (DIC), 125 dizygotic twins, 56-7 doctors, see health professionals double decidual sac sign (DDSS), 53-4,55 Down syndrome, Australia (Vic), 240 early medical abortion (EMA), 62-70 analgesia, 67, 103 antibiotics, prophylactic, 66 contraindications, 66

methotrexate, see methotrexate mifepristone, see mifepristone misoprostol, see misoprostol 'off-label' drugs, 63 follow-up, 68 by telephone, 68 gestation sac in, 66 infection, 68 management, 67-8 mortality and, 123 pain during, 103 process, 64 protocols, 66-7 setting, decision-making process, 65 ectopic pregnancy, 166 Education for Choice, 251 electric pump (EVA), 76 email, 229 embryo cardiac activity, 54 definition, 54 moral worth, 19 ultrasound, 54-5, 56 emergency contraception, 179 emotional wellbeing contradictory feelings, 37-8 postabortion, 39, 111 preabortion, 37-8 ultrasound image viewing, 58-9 see also support and counselling enacted stigma, 185 endometritis, see infection postabortion (endometritis) epidemiology, 24-33 abortion ratio, 28-9 association and causality, see association and causality demographic factors, 29-30, 35, 114 age profiles, see age profiles marital status, 29 social determinants, 30 historical perspectives, see historical perspectives legal abortions, 10 legal considerations and, 29 measurement, 24-5 abortion incidence complications method (AICM), 25 regression equation approach, 25

drugs

internet, from the, 69

258

Index

epidemiology (cont.) prevalence, see prevalence repeat abortions, see 'more than one abortion' unsafe abortion, 24 epilepsy, 138 ethics, 16-23 conscience, see conscience/ conscientious acts in counselling, 50 personhood, criteria for, 17-18 moral worth, 19 potentiality, see potentiality policies, see policies professional responsibilities, 188-9 rights individual's, see rights ownership rights, 17, 21 sex selection, 206-7 viability, see viability Exhale, 251 failed pregnancies, ultrasound scanning, 57-8 felt stigma, 185 fertility, 165, 176-7 fetal anomaly, 143-4, 153-62 counselling following diagnosis, 155-6 medical conditions, 154, 155 patterns and trends, 153-5 prevalence of abortion, 154 prevalence of anomalies, 153-4 termination of pregnancy for, see TOPFA (termination of pregnancy for fetal anomaly) fetal reduction, see feticide fetal remains, 216 feticide, 142-52 definition, 142 dilatation and evacuation (D&E) 94 failed feticide, 151 fetal anomaly termination for, see TOPFA (termination of pregnancy for fetal anomaly); see also fetus fetal reduction, 56, 143 risks, 143 higher gestation abortion and, 143-4, 151 indications, 142-4 medical abortion (higher gestation), 85-6

methods, 85, 144-5 digoxin, see digoxin mechanical, 144 pharmacological, 144, 145-6 potassium chloride, see potassium chloride (KCl) (intracardiac) risks, 145-6 opinions/attitudes, of health professionals, 146-8 research evidence, 144 Royal College of Obstetricians and Gynaecologists (RCOG) recommendations, 85-6, 143-4, 145, 146, 159 selective feticide, 143 settings, 146-8 Society of Family Planning (SFP) (USA), 144 unintended live births, 143, 159 RCOG guidelines, 143-4 fetus definition, 54 moral worth, 19 pain, 178 ultrasound (first trimester), 55 viability, see viability of fetus FIAPAC, 252 fibroids, uterine, 139 FIGO (International Federation of Gynecology and Obstetrics), 252 Finland, 204 first trimester abortion during, see early medical abortion (EMA) ultrasound scanning, see ultrasound scanning follow-up, 106-13 complications, detection of, 109-10 confirmation of a successful abortion, 106-7 exclusion of a continuing pregnancy, 107-9, 110, 127-8, 130 self-assessment, 107, 109 urinary tests, see pregnancy guidelines (RCOG, WHO), 106 indications, 106 patient compliance, 107 procedure types early medical abortion (EMA), see early medical abortion (EMA) medical abortion, 106

outpatient abortion, 68 termination of pregnancy for fetal anomaly (TOPFA), 159-60 vacuum aspiration abortion (VA), 78, 106 telemedicine, 233 ultrasound scanning, 107 forceps, 93 dilatation and evacuation (D&E), 93 McClintock forceps, 93 ring forceps, 93 Frankenhauser plexus, 98 funding historical, 8 NHS funded abortions, 133 second trimester abortions, 204 gemeprost, 82 general anaesthesia, 102 characteristics, 102 levels of sedation, 100 deep sedation, 101, 102 medical co-morbidity and, 134 postoperative pain, decreasing, 102 regimens, 102 General Medical Council (GMC) (UK), conscientious objection, 213 general practitioners (GPs), judgementalism, 215-16 gestational age early abortion, see early medical abortion (EMA) higher gestation, see higher gestation abortion late/second trimester abortions, see second trimester abortion terminology, 201 gestational limit, 181, 201, 202 gestation sac, 53, 54 double decidual sac sign (DDSS), 53-4, 55 in early medical abortion, 66 mean sac diameter (MSD), 53 pseudosac, 55 yolk sac, 54 grief resolution, 89 Guttmacher Institute, 252 Gynuity Health Projects, 252

haematometra, 126

Index

haemorrhage disseminated intravascular coagulopathy (DIC), 125 misoprostol and, 128 surgical abortion, 125 hCG measurement, postabortion, 107, 115 healthcare providers, see health professionals health professionals, 211-18 attitudes to abortion, see attitudes to abortion categories of healthcare providers, 217 mid-level providers, see midlevel providers midwives, 221, 222-3 conscience and, see conscience/ conscientious acts conscientious objection, see conscience/ conscientious acts information provision, 214-15 judgementalism, 215-16 general practitioners (GPs), 215 - 16non-judgemental care, 215 medical abortion and, 216 mortality and, 123 personal challenges, 211-12 'inoculation theory', 212 length of service, 212 therapeutic bond, 211 professional responsibilities, 188-9 role of, 211 shortage of, 219, 224 specific challenges, 216-17 advanced gestation, 216 fetal remains, 216 more than one abortion, 216-17 support and counselling, role in, 217 unpopular work, 214-15 'stigma by association', 214 Hegar dilator, 74 hepatic impairment, 136 higher gestation abortion definition, 81 medical abortion, see medical abortion termination of pregnancy for fetal anomaly (TOPFA), 154-5, 160-1 see also second trimester abortion; third trimester abortion

high sensitivity urine pregnancy test (HSUP), 107, 109 historical perspectives, 6-15, 175 attitudes, see attitudes to abortion in Australia, 237-9 frequency of abortion, 8-10 funding, 8 maternal mortality, 9 methods of abortion, 6-8 criminal abortion, 8 infanticide, 7 medical, 6-7, 62, 80-1 self-abortion, 7 surgical, 7 procurement of abortion, 12 stigma, 9 home, abortion at, see outpatient abortion Hong Kong, 170-1 human chorionic gonadotrophin (hCG), 107, 115 human immunodeficiency virus (HIV) infection, 138 human rights, 244-50 access to abortion, 248-9 denied abortion, 248 social inequality, 248 International Conference on Population and Development (ICPD), see International Conference on Population and Development (ICPD) law reform, 246-8 legal rights, 245-6 governance, 245 Protocol to the African Charter on Human and Peoples' Rights on the Rights of Women in Africa, 247 public health limitations, 248 political consensus and, 244-5 social inequality, 248 unsafe abortion, 244-6 reproductive rights, 244 right to conscience, 187 hypertonic saline, 80-1 Ibis Reproductive Health, 252

illegal abortions, *see* unsafe abortion incomplete abortion, *see* retained products of conception (RPOC)

Individual Level Abortion Stigma (ILAS) scale, 186 infanticide, 7, 19 infection postabortion (endometritis), 127 antibiotics, see antibiotics medical abortion, 129 early medical abortion, 68 mortality and, 129 retained products of conception (RPOC) and, 127 information, patient, 214-15 telemedicine, 233 informed decision, 43 'inoculation theory', 212 Institute of Cemetery and Crematorium Management (ICCM), 216 internalized stigma, 185 international approaches Africa, 247 anaesthesia, 65, 72, 73, 102 Australia, see Australia Canada, 228-9, 231-2 Czech Republic, 171 Finland, 204 Hong Kong, 170-1 Nepal, 224 prevalence (safe/unsafe), 26 Romania, 31 Scandinavia, 36 Sweden, see Sweden Tasmania, see Australia UK, see UK USA, see USA International Conference on Population and Development (ICPD) reproductive rights, 244 unsafe abortion, 244-5 International Consortium for Medical Abortion (ICMA), 252 International Federation of Gynecology and Obstetrics (FIGO), 252 International Planned Parenthood Federation (IPPF), 252 internet medical abortion and, 229 early medical abortion (EMA), 69 website only (Women on Web), 229-30, 231-2 intrauterine device (IUD), 111 Ipas, 253

260

Index

Karman cannula (VA), 74, 75

laminaria, 84 dilatation and evacuation (D&E), 91 late abortions, see second trimester abortion legal considerations attitudes, see attitudes to abortion Australia, see Australia availability of care and, 219-20 banning abortion, 181 decision-making process and, 50 epidemiology and, 24-5, 29 fetal anomaly (TOPFA), 153 gestational age, 201 gestational limit, 181, 201, 202 human rights and, see human rights international, 203 mortality rate and, 123 repeat abortions and, 196 safe/unsafe abortions and, 31 second trimester abortions, 203.209 sex selection, 19 task shifting/sharing, see midlevel providers telemedicine abortion service, 232-3 legislation, see Abortion Act 1967; policies lidocaine, 99 local anaesthesia (surgical abortions), 99-101 additives for PCB (paracervical block), 100-1 allergic reactions, 99 amides, 99 compared to placebo or no intervention, 100 injection site, 99, 101 technique, 101 long-acting reversible contraceptive (LARC), 115, 119 long-term outcomes, see outcomes low sensitivity urine pregnancy test (LSUP), 107, 108-9 male progenitors decision-making and, 35-6

rights, 20–1 manual pump (MVA), 76, 77 Marie Stopes International (MSI), 253 marital status, 29 McClintock forceps, 93 mean sac diameter (MSD), 53 medical abortion complications, see complications of abortion early, see early medical abortion (EMA) for fetal anomaly, 156 follow-up, 106 health professionals and, 216 higher gestation abortion (after 9 weeks), 80-7, 89 9 to 13 weeks' gestation, 83 13 to 24 weeks' gestation, 83-4 definition, 80 feticide before abortion, 85-6 laminaria, 84 methods, 81 osmotic dilators, 84 pain management, see pain management preabortion, 84 assessment, 84 prevalence, 80 prostaglandins, see prostaglandins safety, 80 history of, 6-7, 62, 80-1 mid-level providers, role of, see mid-level providers pain management, see pain management postabortion care, contraception, 111, 118 rates of complete and complications, 65 refusal to provide abortion care, 188 see also conscience/ conscientious acts settings, 64, 220 clinic, 64 contraindications, 65 home, see outpatient abortion medical co-morbidity, 135 telemedicine, see telemedicine vs surgical abortion, 64-5 unsafe abortion, 85 vacuum aspiration, see vacuum aspiration medical co-morbidity, 133-41 anticipated surgical problems, 139-40

physical disabilities, 140 trophoblastic disease, 140 twin pregnancy, 140 uterine conditions, 139 conditions, 133 contraception, 140 general principles of management, 134-5 anaesthesia, see anaesthesia cervical preparation, 134 environment, 135 ultrasound, 134 specific medical conditions, 135-8 acute intermittent porphyria, 137 anaemia, 136 asthma and respiratory diseases, 136 cardiovascular disease, 138 diabetes, 135-6 epilepsy, 138 hepatic impairment, 136 human immunodeficiency virus (HIV) infection, 138 obesity, see obesity platelet disorders, 137 psychiatric conditions and substance misuse, 138 renal disorders, 136 sickle cell disease, 137 thrombophilias, see thrombophilia thyroid disease, 136 see also morbidity mental health, 138, 168-70 abortion and, 20 myths, 177 'postabortion syndrome', 168-9 risk factors, 177 methotrexate, 68-9 administration, 69 teratogenic potential, 69 mid-level providers, 219-26 definition, 219 legal restrictions to task shifting/ sharing, 220 medical abortion experiences of mid-level providers, 222-3 role in, 220 settings, 220 training, 221 midwives, 221, 222-3 Nepal, 224

Index

postabortion care, 223 contraception, 223 surgical abortion experiences of mid-level providers, 221-2 morbidity, 221-2 Sweden, 222-3 training, 221 task sharing, 220, 224-5 task shifting, 219-20 training of, 220-1 midwives, mid-level provision, 221, 222-3 mifepristone, 82 administration (EMA), 67 in Australia, 63 history of, 62-3 indications, 63 9 to 13 weeks' gestation, abortion at, 83 13 to 24 weeks' gestation, abortion at, 83-4 dilatation and evacuation (D&E), 92 teratogenic effect, 130 miscarriage, 64, 165-6 misinformation, see myths and misinformation misoprostol, 82 gestation age 9 to 13 weeks' gestation, abortion at, 83 13 to 24 weeks' gestation, abortion at, 83-4 haemorrhages and, 128 history of, 63 procedures dilatation and evacuation (D&E), 92 early medical abortion, 67, 103 vacuum aspiration abortion (VA), 73 retained products of conception (RPOC), 126, 129 as a single agent 9 to 13 weeks' gestation, 83 13 to 24 weeks' gestation, 83 early medical abortion, 69 teratogenic effect, 130 unsafe abortions, 69 uterine scar rupture, 86 Misoprostol in Obstetrics and Gynecology, 253 monozygotic twins, 56-7 moral issues, see ethics

morbidity (abortion-related), 30-1, 65, 122-32 antibiotics and, 123 digoxin, feticide with, 94 follow-up, detection at, 109-10 incomplete abortion, see retained products of conception (RPOC) mortality, see mortality myths, 176 prevalence, 122-3 rates, 65 in safe abortions, 123-4 second trimester abortions, 202 stigma and, 190 see also complications of abortion; medical comorbidity 'more than one abortion', 193–200 attitude of healthcare providers, 193, 216-17 comparative studies, 197-8 contraception and, 193, 198-9 definition, 194 demographics, 195, 196-7, 204 liberalization of law and, 196 steady state, 196-7 intervals, 197 prevalence, 194, 195, 197 worldwide statistics, 194-6 risk factors, 115-7, 198 postabortion contraception, 115 - 7socio-economic factors, 115 terminology, 193-4 mortality, 10, 11, 30-1, 219 abortion methods and, 123-4 dilatation and evacuation (D&E), 89, 94 early medical abortion (EMA), 123 misoprostol, 69 causes, 122, 123 see also morbidity historical, 9 infanticide, see infanticide infection, 129 early medical abortion, 68 legal considerations legality and, 30 liberalization of abortion law and, 123 myths, 176 Romania, 31 safe procedures, 122 stigma and, 190

unsafe abortions, 30, 114, 122 uterine scar rupture, 86 multiple-order gestations fetal reduction, see feticide ultrasound scanning, 56 myths and misinformation, 175-83 contraception advice, 181-2 efficacy, 179-80 emergency, 179 fertility, 176-7 fetal pain, 178 harm from abortion, 176 higher gestation abortion, 180 - 1legal considerations, 181 mental health issues, 177 mortality and morbidity, 176 prevalence of abortions, 180 reliable sources of information, 176 support and counselling (preabortion), 178-9 National Abortion Federation (NAF), 253 National Health Service (NHS), funded abortions, 133 Nepal, mid-level providers, 224 non-judgemental care, 215 see also health professionals non-steroidal anti-inflammatory drugs (NSAIDs), 85 dilatation and evacuation (D&E), 91 Nursing and Midwifery Council (NMC) (UK), conscientious objection, 213 obesity, 135 anaesthesia and, 135 cervical preparation, 135 higher gestation abortion, 135 Offences Against the Person Act (OAP) (1861, Australia), 237 'off-label' drugs, 63 organizations, 251-4 ACOG, see American Congress of Obstetricians and Gynecologists (ACOG)

262

Index

organizations (cont.) Advancing New Standards in Reproductive Health (ANSIRH), 251 Association of Reproductive Health Professionals (ARHP), 251 Center for Reproductive Rights, 251 Concept Foundation, 251 Education for Choice, 251 Exhale, 251 FIAPAC, 252 FIGO (International Federation of Gynecology and Obstetrics), 252 Guttmacher Institute, 252 Gynuity Health Projects, 252 Ibis Reproductive Health, 252 International Consortium for Medical Abortion (ICMA), 252 International Federation of Gynecology and Obstetrics (FIGO), 252 International Planned Parenthood Federation (IPPF), 252 Ipas, 253 Marie Stopes International (MSI), 253 Misoprostol in Obstetrics and Gynecology, 253 National Abortion Federation (NAF), 253 Nursing and Midwifery Council (NMC) (UK), 213 Planned Parenthood Federation of America, 253 Population Council, 253 Postabortion Care (PAC) Consortium, 253 RCOG, see Royal College of Obstetricians and Gynaecologists (RCOG) United Nations, 254 WHO, see World Health Organization (WHO) osmotic dilators, 84 Dilapan-S®, 91 dilatation and evacuation (D&E), 91 laminaria, see laminaria placement (D&E), 91-2 outcomes, longer-term, 163-74 adverse, risk factors, 45

association and causality, see association and causality breast cancer, 168, 169, 177-8 complications/morbidity, see complications of abortion; morbidity denied abortion, see denied abortion ectopic pregnancy, 166 fertility, 165, 176-7 miscarriage, 165-6 physical health, 165-70 placenta praevia, 166 placental abruption, 166 pre-eclampsia, 167 preterm delivery, 167-8 psychological, 39, 165-70 emotional issues, see emotional wellbeing identification of, 40 mental health, see mental health support and counselling, see support and counselling in USA, 171 outpatient abortion home, 36, 64, 67 follow-up, 68 support and counselling, 65 ovulation, after abortion, 110-11, 115 ownership rights, 17, 21

pain anxiety and, 102-3 early medical abortion (EMA), 103 factors affecting, 98 Frankenhauser plexus, 98 mechanism, 98 postoperative, 102 pain management, 98-105 medical abortion first trimester, 103 higher gestation, 85, 103 non-steroidal antiinflammatory drugs (NSAIDs), 85 surgical abortion, 99-102 adjunct medications, 101 anaesthesia, see anaesthesia non-pharmacological pain management, 102-3 procedural sedation

(moderate IV sedation), 101 types, 98, 104 anaesthesia, see anaesthesia analgesia, see analgesia deep sedation, 98 placebo, 100 paracervical block (PCB) additives for, 100-1 sites, 99 partner(s) support, 205 violence, 199 patient compliance, 107 patient information, see information, patient philosophical approaches, attitudes to abortion, 10-11 physical disabilities, 140 placental conditions placenta accreta abortion and, 86 dilatation and evacuation (D&E), 90 placenta praevia, 166 placental abruption, 166 planned parenthood, abortion requests and, 36 Planned Parenthood clinic (Iowa, USA), 227-8, 230-1 Planned Parenthood Federation of America, 253 platelet disorders, 137 policies, 20 counselling and, 42-3 Population Council, 253 postabortion care complications, see complications of abortion contraception, see contraception dilatation and evacuation (D&E), 95-6 hCG measurement, 107, 115 mid-level providers, see midlevel providers patients, information for, 112 Postabortion Care (PAC) Consortium, 253 ultrasound, role of, 59-60 RCOG guidelines, 59 'postabortion syndrome', 168-9 post-mortem examination, **TOPFA** (termination of pregnancy for fetal anomaly), 158 postnatal abortion, see infanticide

Index

263

potassium chloride (KCl) (intracardiac) feticide, 85, 94, 145 procedure, 148-50 Chiba needle, 148, 149, 150 potentiality, 18-19 moral worth, 19 'pro-life' approach and, 18 preabortion care decision-making, see decisionmaking process support and counselling, see support and counselling ultrasound scanning, 58-9 pre-eclampsia, 167 pregnancy continuing (postabortion), see follow-up contradictory feelings, 37-8 decision-making, 34 ectopic, 166 miscarriage, 64, 165-6 preterm delivery, 167-8 progesterone, 62 twin pregnancy, 56-7, 140 ultrasound scanning, see ultrasound scanning urinary pregnancy tests, 107 high sensitivity (HSUP), 107, 109 low sensitivity (LSUP), 108-9 'qualitative', 107 semi-quantitative, 109 preterm delivery, 167-8 prevalence, 25 abortion for fetal anomaly (TOPFA), 154 by legality, 28 'more than one abortion' population, see 'more than one abortion' myths, 180 NHS funded abortions, 133 of TOPFA (termination of pregnancy for fetal anomaly), 154 unsafe abortions, 26, 28 procedural sedation, see pain management procurement of abortion, 12 progesterone, 62 receptor modulators, see mifepristone 'pro-life' approach, potentiality and, 18

propofol, 102 prostaglandins, 81 administration, 81 analogues, 81-2 gemeprost, 82 misoprostol, see misoprostol sulprostone, 82 Protocol to the African Charter on Human and Peoples' Rights on the Rights of Women in Africa, 247 providers, see health professionals Providers Share Workshop, 186–7 pseudosac, 55 psychological impact of delayed abortions, 202-3 of denied abortion, see denied abortion mental health, see mental health termination of pregnancy of fetal anomaly (TOPFA), 160 psychosocial factors abortion requests, 34-41 demographics, see epidemiology male partners, 35-6 planned parenthood, 36 Scandinavia, 36 social perspectives, 38-9 public attitudes, see stigma public health issues, see human rights

ratio, abortion, 28-9 regression equation approach, 25 renal disorders, 136 repeat abortions, see 'more than one abortion' Reproductive Health (Access to Terminations) Act 2013 (Tas), 241 reproductive rights, 244 research on abortion, limitations, 37 retained products of conception (RPOC) after medical abortions, 129-30 management, 129 after surgical abortions, 126 dilatation and evacuation (D&E), 95 vacuum aspiration abortion (VA), 77 endometritis and, 127 fetal anomaly, abortions for, 157 haemorrhage and, 125

management, 126 risk of failed abortion, 65 symptoms, 126 ultrasound, role of, 59, 126 right of conscience, 188 rights human, see human rights male progenitors, 20-1 ownership, 17, 21 pregnant women's, 16-17 ring forceps, 93 risk of failure (abortion), 65 see also retained products of conception (RPOC) Romania, mortality, 31 Royal College of Obstetricians and Gynaecologists (RCOG), 253 conscientious objection, 213 feticide, recommendations pertaining to, 85-6, 143-4, 145, 146, 159 follow-up, 106 periabortive antibiotic prophylaxis, 127 ultrasound scanning in abortion care, 59 RU-486, see mifepristone safety dilatation and evacuation (D&E), see dilatation and evacuation (D&E) safe procedures, 80, 122, 123-4 vacuum aspiration abortion (VA), 71-2 see also complications of abortion Scandinavia, psychosocial factors in abortion, 36 second trimester abortion, 201-10 antecedent factors, 204-8 age, 204 non-western countries, 206 sex selection, 206-7 UK, 206 complications and adverse effects, 157, 202 contextual issues, 203-4 denied abortion, 202 feticide and, 143-4, 151 funding, 204 gestational limit, 181, 201, 202 indications, 180 legal considerations, 203, 209 methods, 88

264

Index

second trimester abortion (cont.) medical abortion, see medical abortion pain management, 103 settings, 146, 147 surgical abortion, see surgical abortion morbidity, 130 myths, 180-1 obesity and, 135 partner support, 205 regulations, 203 stigma and, 201-2 termination of pregnancy for fetal anomaly (TOPFA), 154-5 terminology, 201 USA, 204-5 see also higher gestation abortion sedation levels, 100 conscious, see pain management deep, 101 general anaesthetic, see general anaesthesia procedural, see pain management selective feticide, 143 self-abortion, 7 semi-quantitative urinary pregnancy test, 109 settings for abortion feticide, see feticide higher gestation abortion, 146, 147 medical abortion, see medical abortion statistics, 146 TOPFA (termination of pregnancy for fetal anomaly), 159 vacuum aspiration abortion (VA), 73 sex-selective abortion, 19-20, 206-7 culture and, 20 legal considerations, 19 sexually transmitted infections (STIs) Chlamydia trachomatis, 66, 127 screening, 66 sickle cell disease, 137 social inequality, 248 Society of Family Planning (SFP) (USA), feticide, 144

socio-economic factors, 30, 35 of male partner, 35 risk factors for subsequent abortion, 115, 116 staff, see health professionals stigma, 12, 39, 184-92 conceptualization, 184-5 definition, 184 domains, 185 enacted stigma, 185 felt stigma, 185 internalized stigma, 185 conscience and, 187 experience of, 39-40 historical perspectives, 9 late abortion and, 201-2 measurement, 185-6 Individual Level Abortion Stigma (ILAS) scale, 186 methodologies, 185-6 qualitative tools, 186 quantitative tools, 186 Stigmatizing Attitudes Beliefs and Actions Scale (SABAS), 186 mortality/morbidity and, 190 reduction interventions, 186-7, 190 culture of support, 187 Providers Share Workshop, 186-7 'stigma by association', 214 Stigmatizing Attitudes Beliefs and Actions Scale (SABAS), 186 substance use, 138 suction evacuation/curettage, see vacuum aspiration abortion (VA) sulprostone, 82 support and counselling culture of support (stigma reduction intervention), 187 ethics in, 50 fetal anomaly, 155-6 health professionals, role of, 217 outpatient abortion, 65 partner support, 205 postabortion, 48 function and timing, 49 preabortion, 42-51 compulsory counselling, 42 counselling techniques, 47-8 functions of, 46 identification of needs, 44, 45

intense level, 44-6 myth, 178-9 policy context, 42-3 resistance to, 46 professional care, 49-50 boundaries and personal feelings, 50 core principles, 49 qualifications, 49 telemedicine, 233 TOPFA (termination of pregnancy for fetal anomaly), 160 see also emotional wellbeing surgical abortion, 7 complications, see complications of abortion for fetal anomaly, 156, 157 higher gestation, 89 vs medical abortion, 64-5 methods dilatation and evacuation (D&E), see dilatation and evacuation (D&E) vacuum aspiration, see vacuum aspiration abortion (VA) mid-level providers, role of, see mid-level providers pain management, see pain management postabortion care, contraception, 96, 111, 117-18 pre-procedure medication, 101 rates of complete and complications, 65 ultrasound, role of, 59 Sweden, 171 mid-level provision, 222-3 taboo, see stigma task sharing, see mid-level providers task shifting, 219-20 Tasmania, see Australia technology, fetus viability and, 21 telemedicine, 227-35 applications, 227 definition, 227 development guidelines, 232-3 consent/information/

support, 233

gestational dating and

investigations, 233

follow-up, 233

© in this web service Cambridge University Press

Index

hardware/software, 233 regulatory and licensing issues, 232-3 evaluation strategies, 230-2 medical abortion, 227-30, 232 Canada (Women on Web), 228-9, 231-2, 254 clinic to clinic, 227-8 clinic to woman at home, 228-9 internet and email, 229 internet website only, 229-30 Planned Parenthood clinic (Iowa, USA), 227-8,230-1 telepharmacy, 228 telephone, follow-up (EMA), 68 teratogens methotrexate, 69 mifepristone, 130 misoprostol, 130 termination of pregnancy for fetal anomaly, see TOPFA (termination of pregnancy for fetal anomaly) therapeutic bond, 211 third trimester abortion, 160-1 pain management, 103 termination of pregnancy for fetal anomaly (TOPFA), 154-5, 160-1 thrombophilias, 137 venous thromboembolism (VTE), 137 thyroid disease, 136 TOPFA (termination of pregnancy for fetal anomaly) Australia (Victoria), 240 cremation and burial, 159 decision-making factors, 155-8 availability, 158 complications and adverse effects, 157 post-mortem examination, 158 preference and acceptability, 157-8 gestational age, 154-5, 160-1 hospital follow-up visit, 159-60 legal criteria, 153 medical conditions, see fetus methods, 155, 156 anaesthesia, 156 feticide, 158-9 medical abortion, 156

setting, 159 surgical, 156, 157 prevalence of, 154 psychological impact, 160 counselling, 160 retained products of conception, 157 in third trimester, 160-1 training of mid-level providers, see midlevel providers second trimester abortion, 89 ultrasound targeted training, 58 transabdominal (TA) transducers, 52, 56, 57 transvaginal (TV) transducers, 52, 54, 55 twin pregnancy, 56-7, 140

UK

gestational limit, 181 repeat abortion statistics, 196 second trimester abortions, 206 ultrasound (first trimester), 57 ultrasound scanning, 52-61 abortion care and, 58-60 image viewing, patients, 58 - 9intraoperative assessment, 59 postabortion, 59-60 preabortion assessment, 58-9 RCOG guidelines, 59 targeted training, 58 applications, 53, 59-60 in failed pregnancies, 57-8 first trimester, 53-5 embryo and fetus, 54-5, 56, 57 gestation sac, see gestation sac medical co-morbidity, 134 multiple gestations, 56-7 objectives, 52 postabortion, 107 procedures dilatation and evacuation (D&E), 90 vacuum aspiration abortion, use in, 72 of retained products of conception (RPOC), 59, 126 sonoembryological development, 55-6 biparietal diameter, 56 techniques, 52 transabdominal (TA)

transducers, 52, 56, 57 transvaginal (TV) transducers, 52, 54, 55 unintended live births, see feticide United Nations, 254 unsafe abortion, 24, 175 contraception, postabortion, 114 definition, 122 human rights and, 245-6 International Conference on Population and Development (ICPD), 244-5 interventions, 246 legal abortion and, 31 medical abortion, 85 misoprostol, 69 mortality and, 30, 114, 122 prevalence, 26, 28 as a public health issue, 244 urinary pregnancy tests, see pregnancy USA conscientious objection, 213-14 outcomes, 171 Planned Parenthood clinic (Iowa), 227-8 second trimester abortions, 204 - 5uterus fibroids, 139 perforation dilatation and evacuation (D&E), 94 management, 125 risk factors, 124 surgical abortion, 124-5 rupture, medical abortion (higher gestation), 84-5, 86, 130 scar rupture, 139 dilatation and evacuation (D&E) and, 86 maternal mortality, 86 misoprostol, 86 placenta accreta, 86 uterine sounding (VA), 75

vacuum aspiration abortion, *see* vacuum aspiration abortion (VA) dilatation and evacuation (D&E), 93 retained products of conception (RPOC), 126

266

Index

vacuum aspiration abortion (VA), 71-9 acceptability, 72 complications, 76-8, 123-4 incomplete evacuation, 77 definition, 71 efficacy, 71 history of, 71 indications, 71 post-procedure management, 78 follow-up, 78, 106 pre-procedure, 73 antibiotics, 73 cervical dilation, 75 cervical preparation, 73 cervical traction, 74-5 informed consent, 72 initial assessment, 72-3

misoprostol, 73 pain management, 73 procedure, 74-6 aspiration, 75-6 bimanual examination, 74 cervical dilation, 75 cervical traction, 74-5 equipment/instruments, 74 Hegar dilator, 74 Karman cannula, 74, 75 uterine sounding, 75 safety, 71-2 settings, 73 ultrasound scanning, 72 vacuum source, 71 electric pump (EVA), 76 manual pump (MVA), 76, 77

vasovagal reaction, surgical abortion, 124 venous thromboembolism (VTE), 137 viability of fetus, 21–2 definition, 22 technology dependent, 21 Victoria, *see* Australia

Western Australia, 239 Women on Web, 228–9, 231–2, 254 World Health Organization (WHO), 254 follow-up, 106 safe abortion, 129

yolk sac, 54